1. /
  2. Commercialisation /
  3. Partner with us
Commercialisation
241030 POC Syphilis 1

Partner with us

Bringing innovation to market. For nearly 40 years, Burnet has worked to address the most pressing global health challenges and ensure no one is left behind.

Elsiewilliams 240215 Lcrabb Burnet 588 RESIZE

Our difference

We’re more flexible and agile than university- or government-based institutes.

We work across Asia Pacific and collaborate on projects in other continents.

Our technical capacity spans the full research lifecycle – from laboratory research through to implementation and clinical applications.

Current partnering opportunities

Stellabody®

  • Transformative technology that improves the efficacy of cancer, inflammation and infectious disease treatments.
  • Up to 100 times more effective at cell killing than standard antibody therapeutics.

Learn more about Stellabody®.

Diagnostics

  • Point-of-care test for liver function.
  • Active syphilis diagnosis.
  • Diagnostic assay for measurement of dimeric IgA.
  • Diagnostic development service facility.

Learn more about our diagnostics work.

Vaccines

  • Platform technology for development of stable coronavirus vaccines including MERS.
  • Hepatitis C vaccine.
  • Malaria vaccine.

Learn more about our vaccines work.

Ageing and inflammation

  • Biomarkers.
  • Ageing B-cells.

Learn more about our work in ageing and inflammation.

Microbiome

  • Gel for optimal vaginal microbiome.
  • Model for vaginal–microbiome host interactions.

Learn more about our microbiome work.

Public and international health

  • Technical expertise to support and strengthen health systems.
  • Responses to health challenges in the Asia Pacific region.
  • Research and modelling collaborations with partners worldwide.

Our team

Jennifer Barnes

Jennifer Barnes

Director, Commercialisation and Research Translation; Director, Burnet Diagnostics Initiative
Seasoned commercialisation executive with over 20 years' success working with scientists to translate research into market-ready health solutions. Brings a diverse background across science, marketing, sales, strategy, and business development, with a focus on diagnostics and medical devices. Experienced in large multinationals, as a start-up founder and CEO, and in executive leadership within the medical research sector.
jennifer.barnes@burnet.edu.au
View profile
Professor Heidi Drummer

Professor Heidi Drummer

Scientific Director for Research Translation; Scientific Director, Burnet Diagnostics Initiative
Scientific director of the Burnet Diagnostics Initiative and co-head of the Viral Entry and Vaccines research group. Internationally recognised as a leader in translational science and viral hepatitis with 30 years' experience in the development of diagnostics, vaccines and therapeutics, and commercialisation of diagnostic assays.
heidi.drummer@burnet.edu.au
View profile
Carli Roulston

Carli Roulston

Senior Manager, Business Development
Over 25 years’ experience in medicine and medical device development. Extensive experience in attracting funding, investment and partnerships to research. Former head of commercialisation at The Florey Institute. PhD in pharmacology from Monash University.
carli.roulston@burnet.edu.au
View profile
Geoff Drenkhahn

Geoff Drenkhahn

Chief, Funding Growth
Over 30 years’ experience in the Research and Development (R&D) sector, including 8 years as the inaugural chief operating officer at Burnet Institute. Instrumental role in the growth of Burnet including identifying alternative funding avenues such as the commercialising of Burnet technologies and the establishment and eventual sale of 360biolabs. Holds MBA in technology management, and completed leadership programs at MIT and Harvard Business School.
geoff.drenkhahn@burnet.edu.au
View profile
Png Tb Clinic

Accredited NGO

Burnet is the only medical research Institute that is fully accredited by the Australian Government as a non-government organisation. This enables us to work with communities and take discoveries in real-world settings to improve health equity.

We have offices in Papua New Guinea and Myanmar, and contribute to research and public health programs in other countries across Asia, the Pacific, Africa, Europe, and North America.

Our track record

360biolabs

Founded in 2015, Burnet’s business 360biolabs became Australia’s most diverse bioanalytical and specialty laboratory offering science-driven expertise and laboratory services for Phase I-III clinical studies. 

The high quality of trials and experience of the team was quickly recognised, culminating in the sale to biotech organisation BioAgilityx for AUD$282 million.

Burnet Diagnostics Initiative

Our ISO 9001-certified group produces commercially viable, accurate and low-cost products for unmet health needs:

  • developed the WHO-endorsed VISITECT® CD4, the first equipment-free point of care test to monitor HIV disease progression
  • licensed multiple diagnostic assays in international markets (hepatitis E, CD4 HIV and syphilis)
  • offers a fee-for-service diagnostic research, development work and customisation service.

Burnet Diagnostics Initiative (BDI) logo with the ISO 9001 Quality Management Systems Certified logo. Certification Number: FS 768091

Burnext accelerator program

Our Burnext model fast-tracks translational research by removing funding barriers, which often inhibit researchers developing ideas into real-world outcomes. It takes projects from proof-of-concept to an intense process of milestone-driven project planning and delivery stages, to ensure outcomes within 24 months.

Through Burnext, we are also able to co-invest with potential partners.

Burnet Institute has invested an initial AUD $6.5 million in Burnext.

ISO 9001 certified

Burnet Diagnostics Initiative achieved ISO 9001 Certification in 2023 based on the highest international quality standards including a strong client focus, the process approach and a commitment to continual improvement.

All Burnet research translation activities now have access to the ISO 9001 quality management system. This means we are industry-ready and our collaborators are confident that we conduct our research in an ethical, robust and reproducible way.

Burnet Commercial Capabilities Cover Thumbnail

Download brochure

This brochure contains information about Burnet's capabilities, our track record and impact.

Capabilities brochure [PDF 1.7 MB]
On this page